New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis

Clinical Infectious Diseases

Volumn 47, Issue 12, 2008, Pages 1587-1592

  Chumakov, Konstantin ^a   Ehrenfeld, Ellie ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; LIVE VACCINE; POLIOMYELITIS VACCINE;

DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; HUMAN; IMMUNIZATION; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; VIRUS IMMUNITY; VIRUS TRANSMISSION; WILD TYPE;

HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED;

EID: 56749106906     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/593310     Document Type: Review

References (57)

1. Robbins FC. Polio - historical. In: Plotkin SA, Mortimer EA, eds. Vaccines. Philadephia: W B Saunders, 1988:98-114.
2. Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ, Bazeley PL. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health Nations Health 1954; 44:563-70.
3. Blume SS. Lock in, the state and vaccine development: lessons from the history of the polio vaccines. Research Policy 2005; 34:159-73.
4. Offit PA. The cutter incident: how America's first polio vaccine led to the growing vaccine crisis. New Haven, CT: Yale University Press, 2005.
5. Plotkin SA, Koprowski H, Stokes J Jr. Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics 1959; 23: 1041-62.
6. Melnick JL, Brennan JC. Monkey neurovirulence of attenuated poliovirus vaccines being used in field trials. In: Live polio virus vaccines. Washington, DC: Pan American Health Organization, 1959:65-101.
7. Chumakov MP. The effect of mass peroral immunisation by live vaccines from Sabin strains on the epidemiological process of poliomyelitis. J Hyg Epidemiol Microbiol Immunol 1960; 4:287-8.
8. Sabin AB. Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc 1957; 164:1216-23.
9. Grassly NC, Fraser C,Wenger J, et al. New strategies for the elimination of polio from India. Science 2006; 314:1150-3.
10. Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007; 369:1356-62.
11. van Wezel AL, van Steenis G, Hannik CA, Kapsenberg JG, Hofman B, Cohen H. Preparation and application in the Netherlands of inactivated vaccine against poliomyelitis [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 1979; 123:155-63.
12. Montagnon BJ, Fanget B, Vincent-Falquet JC. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 1984; 6(Suppl 2):S341-4.
13. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992; 14:568-79.
14. McBean AM, Modlin JF. Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Pediatr Infect Dis J 1987; 6:881-7.
15. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356-9.
16. Centers for Disease Control and Prevention. Acute flaccid paralysis associated with circulating vaccine-derived poliovirus-Philippines, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:874-5.
17. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses - worldwide, January 2006-August 2007. MMWR Morb Mortal Wkly Rep 2007; 56:996-1001.
18. Cherkasova EA, Korotkova EA, Yakovenko ML, et al. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 2002; 76:6791-9.
19. Labadie K, Pelletier I, Saulnier A, Martin J, Colbere-Garapin F. Poliovirus mutants excreted by a chronically infected hypogammaglobuli nemic patient establish persistent infections in human intestinal cells. Virology 2004; 318:66-78.
20. Martin J, Odoom K, Tuite G, et al. Long-term excretion of vaccine-derived poliovirus by a healthy child. J Virol 2004; 78:13839-47.
21. Yang CF, Chen HY, Jorba J, et al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol 2005; 79:12623-34.
22. Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev Med Virol 2003; 13:277-91.
23. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. Vaccination against polio should not be stopped. Nat Rev Microbiol 2007; 5:952-8.
24. Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 2002; 297:1016-8.
25. Agol VI, Chumakov K, Ehrenfeld E, Wimmer E. Don't drop current vaccine until we have new ones. Nature 2005; 435:881.
26. Bompart F. Vaccination strategies for the last stages of global polio eradication. Indian Pediatr 2005; 42:163-9.
27. Korotkova EA, Park R, Cherkasova EA, et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol 2003; 77:12460-5.
28. Thompson KM, Tebbens RJ, Pallansch MA, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health 2008; 98:1322-30.
29. Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A 1996; 93:2370-5.
30. Macadam AJ, Ferguson G, Stone DM, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol 2006; 80:8653-63.
31. Arita I, Nakane M. Road map for polio eradication-establishing the link with millennium development goal no. 4 for child survival. Jpn J Infect Dis 2008; 61:169-74.
32. Bhasin VK. Problems with the oral polio vaccine. Nat Med 2008; 14: 9.
33. Ehrenfeld E, Glass RI, Agol VI, et al. Immunisation against poliomyelitis: moving forward. Lancet 2008; 371:1385-7.
34. World Health Organization (WHO). WHO global action plan for laboratory containment of wild polioviruses. 2nd edition. Geneva, Switzerland: WHO, 2004.
35. Doi Y, Abe S, Yamamoto H, et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 2001; 105: 163-9.
36. Dragunsky EM, Ivanov AP, Abe S, et al. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine. J Infect Dis 2006; 194:804-7.
37. Dragunsky EM, Ivanov AP, Wells VR, et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 2004; 190:1404-12.
38. Rezapkin G, Martin J, Chumakov K. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals 2005; 33:29-39.
39. Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007; 25:7041-6.
40. Simizu B, Abe S, Yamamoto H, et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 2006; 34: 151-4.
41. Brown F. Inactivation of viruses by aziridines. Vaccine 2001; 20:322-7.
42. Budowsky EI. Problems and prospects for preparation of killed antiviral vaccines. Adv Virus Res 1991; 39:255-90.
43. Wiktor TJ, Aaslestad HG, Kaplan MM. Immunogenicity of rabies virus inactivated by b-propiolactone, acetylethyleneimine, and ionizing irradiation. Appl Microbiol 1972; 23:914-8.
44. Jiang SD, Pye D, Cox JC. Inactivation of poliovirus with beta-propiolactone. J Biol Stand 1986; 14:103-9.
45. Agol VI, Pilipenko EV, Slobodskaya OR. Modification of translational control elements as a new approach to design of attenuated picornavirus strains. J Biotechnol 1996; 44:119-28.
46. Toyoda H, Yin J, Mueller S, Wimmer E, Cello J. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 2007; 67:2857-64.
47. Domingo E, Martin V, Perales C, Grande-Perez A, Garcia-Arriaza J, Arias A. Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol 2006; 299:51-82.
48. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 2003; 100: 7289-94.
49. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006; 439:344-8.
50. Vignuzzi M,Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 2008; 14:154-61.
51. Comeron JM, Aguade M. An evaluation of measures of synonymous codon usage bias. J Mol Evol 1998; 47:268-74.
52. Burns CC, Shaw J, Campagnoli R, et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J Virol 2006; 80:3259-72.
53. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol 2006; 80:9687-96.
54. Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, Mueller S. Virus attenuation by genome-scale changes in codon pair bias. Science 2008; 320:1784-7.
55. van Rij RP, Andino R. The silent treatment: RNAi as a defense against virus infection in mammals. Trends Biotechnol 2006; 24:186-93.
56. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-9.
57. Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 2006; 193:598-600.